In this observational study conducted in real life conditions, the treatment with Souvenaid for six months, alone or in combination with AChE inhi-bitors, was well tolerated and seemed to be associated to less cognitive impairment deterioration than the treatment only with AChE inhibitors or no treatment in patients with mild AD. The gene discussed is ACHE; the disease is Cognitive impairment.